Recruitment Messages for Current Smokers Recently Diagnosed With Cancer
20 luglio 2022 aggiornato da: University of Oklahoma
A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial
The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer.
To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures.
We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.
Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.
Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
99
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Jordan Neil
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Speak and understand English
- A recent cancer diagnosis (within the past 24 months)
- 18 years or older
- Report any cigarette use within the past 30 days
Exclusion Criteria:
- Do not speak or understand English
- Have not been diagnosed with cancer within the past 24 months
- Below the age of 18
- Does not report any cigarette use within the past 30 days
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione fattoriale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore fittizio: Control
The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
|
Does not include any of the three message factors.
|
|
Sperimentale: Proximal x Cost x Loss
Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
|
|
Sperimentale: Proximal x Cost x Gain
Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
|
|
Sperimentale: Proximal x Benefit x Gain
Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Sperimentale: Proximal x Benefit x Loss
Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Sperimentale: Distal x Cost x Gain
Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Sperimentale: Distal x Cost x Loss
Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Sperimentale: Distal x Benefit x Loss
Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Sperimentale: Distal x Benefit x Gain
Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference in intent to talk to a physician about participating in a smoking cessation study between factors.
Lasso di tempo: Within 30 minutes
|
The main effect within each message factor level was examined using ANOVA and compared with the control condition.
|
Within 30 minutes
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Predictors of intent to talk to a physician about participating in a smoking cessation study.
Lasso di tempo: Within 30 minutes
|
Other message evaluation and effectiveness measures were collected and explored in a multivariable model predicting intent to talk to a physician.
|
Within 30 minutes
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Jordan Neil, Ph.D., TSET Health Promotion Research Center
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
11 febbraio 2019
Completamento primario (Effettivo)
1 aprile 2019
Completamento dello studio (Effettivo)
2 aprile 2019
Date di iscrizione allo studio
Primo inviato
13 luglio 2022
Primo inviato che soddisfa i criteri di controllo qualità
20 luglio 2022
Primo Inserito (Effettivo)
22 luglio 2022
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
22 luglio 2022
Ultimo aggiornamento inviato che soddisfa i criteri QC
20 luglio 2022
Ultimo verificato
1 luglio 2022
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 2018P002035
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .